NCT06309147View on ClinicalTrials.gov

A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's

PHASE1RecruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

February 15, 2025

Study Completion Date

July 15, 2025

Conditions

Parkinson Disease

Interventions

DRUG

BMS-9894923

50 mg capsules, oral administration

Trial Locations (1)

27701

RECRUITING

Duke Clinical Research Institute, Durham

Sponsors

Lead Sponsor

Allyx Therapeutics

All Listed Sponsors

collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Allyx Therapeutics

INDUSTRY

NCT06309147 - A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's | Biotech Hunter | Biotech Hunter